Amsterdam—Promising medications for Chronic Fatigue Syndrome (CFS), too known as Myalgic Encephalomyelitis (ME/CVS), may not be thoroughly investigated due to prohibitive costs, according to a report published on Friday, March 13, 2026.
The Netherlands Organization for Health Research and Development (ZonMw), which distributes research funding on behalf of the government, is currently only providing grants for studies utilizing medications that are no longer under patent. This restriction is intended to avoid high costs and potential legal complications.
An estimated 30,000 to 40,000 people in the Netherlands live with ME/CVS, a complex illness characterized by profound fatigue and cognitive dysfunction. The limitations on research funding raise concerns about the potential to find effective treatments for this debilitating condition, impacting the quality of life for many patients.
The decision to prioritize off-patent drugs means that newer, potentially more effective therapies may be excluded from clinical trials. This approach, whereas fiscally responsible, could hinder progress in understanding and treating ME/CVS.
ME/CVS symptoms include concentration and memory problems, muscle and joint pain, headaches, and fatigue that persists for more than 24 hours after physical or mental exertion. The illness can significantly disrupt daily life, making it tough for individuals to maintain employment, social connections, and overall well-being.
